CDX
OV-90
Tumor indication
Ovarian
Tumor subtype
Ovarian Serous Adenocarcinoma
Description
OV-90 (Ovarian Cancer CDX Model)
The OV-90 line was derived from ascites of a patient with high-grade serous ovarian carcinoma. It represents an aggressive ovarian cancer subtype. OV-90 is widely used in drug testing and biomarker research. Its aggressive growth and reproducibility make it valuable for translational research.
Key Features:
- Derived from high-grade serous ovarian carcinoma.
- Represents advanced ovarian cancer.
- Aggressive xenograft growth.
- Epithelial carcinoma morphology.
Applications:
OV-90 is applied in studies of ovarian cancer therapeutics, including chemotherapy and targeted therapy. Researchers use it to explore resistance mechanisms in serous ovarian carcinoma. It supports biomarker identification for ovarian cancer treatment. Its stability ensures consistent outcomes in preclinical pipelines.
Details
- Tumor indication
- Ovarian
- Tumor subtype
- Ovarian Serous Adenocarcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.